Delving into the Latest Updates on TWB-103 with Synapse

Overview

Basic Info

Drug Type

Cell therapy

Synonyms

TWB 103, TWB103

Target-

Action-

Mechanism

Cell replacements

Therapeutic Areas

Nervous System DiseasesCardiovascular DiseasesEndocrinology and Metabolic Disease+ [2]

Active Indication-

Inactive Indication

Burns, ChemicalDiabetic foot ulcerDonor site complication

Originator Organization

Elanix Biotechnologies AG

Active Organization-

Inactive Organization

Transwell Biotech Co. Ltd.

License Organization-

Drug Highest PhasePendingPhase 1/2

First Approval Date-

Regulation-

Login to view timeline

Primary objective:
1. To evaluate the safety of TWB-103 in split-thickness skin graft donor site wounds (DSW) for Phase I in terms of Incidence of treatment-related AEs and SAEs (including infections and bleeding)
2. To evaluate the efficacy for Phase I+II of TWB-103 in split-thickness skin graft donor site wounds (DSW) in terms of The healing time from DSW creation to 100% re-epithelialization
Secondary objective:
1. To evaluate the efficacy of TWB-103 in split-thickness skin graft donor site wounds (DSW) in secondary efficacy endpoints
2. To evaluate the safety of TWB-103 in split-thickness skin graft donor site wounds (DSW) in secondary safety endpoints

Start Date06 Jul 2017

Sponsor / Collaborator

Transwell Biotech Co. Ltd.

[+1]

100 Clinical Results associated with TWB-103

Login to view more data

100 Translational Medicine associated with TWB-103

Login to view more data

100 Patents (Medical) associated with TWB-103

Login to view more data

100 Deals associated with TWB-103

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetic foot ulcer	Phase 2	Taiwan Province	Transwell Biotech Co. Ltd.	19 Dec 2019
Burns, Chemical	Phase 2	Japan	Transwell Biotech Co. Ltd.	06 Jul 2017
Burns, Chemical	Phase 2	Taiwan Province	Transwell Biotech Co. Ltd.	06 Jul 2017
Donor site complication	Phase 2	Japan	Transwell Biotech Co. Ltd.	06 Jul 2017
Donor site complication	Phase 2	Taiwan Province	Transwell Biotech Co. Ltd.	06 Jul 2017

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02737748 (CTgov)	Phase 1/2	Donor site complication \| Burns, Chemical \| Wounds and Injuries	48	TWB-103 (TWB-103 Group)	gleaenihpz = lnkvtmbqlb oqhoviaams (ypxfzjrhrc, rcbuwfrqoh - enkpaxofgg) View more	-	28 Jul 2023
NCT02737748 (CTgov)	Phase 1/2		48	Placebo Group (Placebo Group)	gleaenihpz = nktnxcjtgy oqhoviaams (ypxfzjrhrc, pjugkhogzt - bpdxzdachp) View more	-	28 Jul 2023
NCT03624023 (CTgov)	Phase 1/2	Diabetic foot ulcer	10	TWB-103	vzwemxrykc = qonqvcqaxy tjgagtawce (clfqstbsgm, wuhqkxeiyo - aiqsqeorkx) View more	-	12 Jul 2023